Pune, India, Dec. 09, 2021 (GLOBE NEWSWIRE) -- The global “adalimumab biosimilar market” is poised to experience a steady growth period owing to the rising incidence of arthritis. According to the World Health Organization (WHO), rheumatoid arthritis affects 0.3 to 1% of people in the developed countries and about 50% of them are forced to quit their jobs after the onset of the disease. On the other hand, osteoarthritis hits 9.6% of men and 18% of women over the age of 60 globally. The Arthritis Foundation predicts that 78 million Americans will be suffering from arthritis by 2040, with 54 million already affected by it. The global adalimumab biosimilar market stands to gain from this growing prevalence as adalimumab is an effective treatment option for various kinds of arthritis.
Request a Sample Copy of the Research Report
https://www.fortunebusinessinsights.com/enquiry/sample/adalimumab-biosimilar-market-100594
A monoclonal antibody, adalimumab is designed to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s Disease, ulcerative colitis, and many more. It achieves this by inhibiting the soluble inflammatory cykotine, Tumor Necrosis Factor (TNF). The product originated from AbbVie’s Humira, which got cleared by the US FDA in 2002 and the European Medicines Agency in 2003.
In its report, titled “Adalimumab Biosimilar Market Size, Share And Global Trend By Product (Exemptia, Adalirel, Cipleumab, Others), By Distribution channel (Hospitals pharmacies, Retail pharmacies, Others), And Geography Forecast Till 2026”, Fortune Business Insights provides an in-depth analysis of this burgeoning market. Additionally, the report contains a comprehensive assessment of the factors, trends, and dynamics that will shape the market during forecast period.
Click here to get the short-term and long-term impact of COVID-19 on this Market.
Please visit: https://www.fortunebusinessinsights.com/industry-reports/adalimumab-biosimilar-market-100594
Proliferation of Skin Disorders to Fuel the Market
According to the WHO, skin afflictions are the most commonly affecting disorders harming human health. The WHO estimates that around 900 million people in the world suffer from skin diseases at any given point of time. Many of these skin disorders lead to lifelong disfigurement, stigma, and disability and treating them effectively has become major concern for health organizations the world over. In this backdrop, adalimumab biosimilar has emerged as a viable treatment option for chronic skin diseases such as eczema. This factor can considerably swell the global adalimumab biosimilar market size in the forecast period. A biosimilar is a biological product having characteristics similar to those of its biologic reference product and targets specific areas in the immune system to treat the disease. Owing to its multiple advantages, especially in treating psoriasis, adalimumab biosimilar is emerging as a preferred option to tackle skin disorders.
Rising Prevalence of Autoimmune Diseases to Drive the Market in North America
The American Autoimmune Related Diseases Association estimates that around 50 million Americans suffer from some kind of autoimmune disease. Moreover, the healthcare costs of treating these diseases is close to USD 100 billion annually. This, along with an increasing aged population, is expected to give North America the largest percentage of the global adalimumab biosimilar market share during the forecast period. Rising geriatric population and increasing public and private investment in pharmaceuticals are factors that will propel the market in Europe. The market in Asia-Pacific is expected to be driven by the growing investments in medicine research.
Have Any Query? Ask Our Experts
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/adalimumab-biosimilar-market-100594
Regulatory Approvals to Spur Competition; Boehringer’s Cyltezo Gets FDA Approval
Cyltezo, a biosimilar of adalimumab developed by Boehringer Ingelheim International, got the green light from the US FDA in August 2017. Such regulatory clearances to novel products are expected to encourage other players to make greater investments in research and development and come out with innovative products. Some players in the global adalimumab biosimilar market are already engaged in developing new products and expanding their product portfolios. For instance, Glenmark Pharmaceuticals launched ADALY, its adalimumab biosimilar drug, in Mumbai in January 2018 through a licensing agreement with Cadila Healthcare.
Fortune Business Insights covers some of the important competitors in the global adalimumab biosimilar market:
- Zydus Cadila
- Alfred E. Tiefenbacher
- Torrent Pharmaceuticals Ltd
- Cipla Inc.
- Glenmark Pharmaceuticals Ltd
- Emcure Pharmaceuticals Ltd
- Boehringer Ingelheim International GmbH
- Reliance Life Sciences
Ask for Customization
https://www.fortunebusinessinsights.com/enquiry/customization/adalimumab-biosimilar-market-100594
Segmentation of the Global Adalimumab Biosimilar Market
By Product
• Exemptia
• Adalirel
• Cipleumab
• Others
By Distribution channel
• Hospitals pharmacies
• Retail pharmacies
• Others
By Geography
• North America (USA and Canada)
• Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
• Latin America (Brazil, Mexico and Rest of Latin America)
• Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email:sales@fortunebusinessinsights.com
